

PHARMACO
CHEMISTRY
LIBRARY

32

TRENDS IN DRUG RESEARCH III

Proceedings of the 13th Noordwijkerhout-Camerino
Symposium

EDITED BY

Henk van der Goot

ELSEVIER

PHARMACOCHEMISTRY LIBRARY - VOLUME 32

TRENDS IN DRUG RESEARCH III

Proceedings of the 13th Noordwijkerhout-Camerino Symposium

PHARMACOCHEMISTRY LIBRARY, edited by H. Timmerman

Other titles in this series

- Volume 24** Perspectives in Receptor Research. Proceedings of the
10th Noordwijkerhout-Camerino Symposium, Camerino (Italy), 10-14 September 1995
edited by D. Giardinà, A. Piergentili and M. PIGINI
- Volume 25** Approaches to Design and Synthesis of Antiparasitic Drugs
edited by Nitya Anand
- Volume 26** Stable Isotopes in Pharmaceutical Research
edited by Thomas R. Browne
- Volume 27** Serotonin Receptors and their Ligands
edited by B. Olivier et al.
- Volume 28** Proceedings XIVth International Symposium on Medicinal Chemistry
edited by F. Awouters
- Volume 29** Trends in Drug Research II. Proceedings of the 11th Noordwijkerhout-Camerino
Symposium, Noordwijkerhout (The Netherlands), 11-15 May, 1997
edited by H. van der Goot
- Volume 30** The Histamine H₃ Receptor. A Target for New Drugs
edited by R. Leurs and H. Timmerman
- Volume 31** Receptor Chemistry towards the Third Millennium. Proceedings of the
12th Noordwijkerhout-Camerino Symposium, Camerino (Italy), 5-9 September 1999
edited by U. Gulini et al.

PHARMACOCHEMISTRY LIBRARY
Editor: H. Timmerman



Volume 32

TRENDS IN DRUG RESEARCH III

Proceedings of the 13th Noordwijkerhout-Camínero
Symposium, The Netherlands, 6-11 May 2001

Edited by:
Henk van der Goot

*Department of Pharmacochémistry, Free University Amsterdam,
The Netherlands*



2002
ELSEVIER

Amsterdam – London – New York – Oxford – Paris – Shannon – Tokyo

ELSEVIER SCIENCE B.V.
Sara Burgerhartstraat 25
P.O. Box 211, 1000 AE Amsterdam, The Netherlands

©2002 Elsevier Science B.V. All rights reserved.

This work is protected under copyright by Elsevier Science, and the following terms and conditions apply to its use:

Photocopying

Single photocopies of single chapters may be made for personal use as allowed by national copyright laws. Permission of the Publisher and payment of a fee is required for all other photocopying, including multiple or systematic copying, copying for advertising or promotional purposes, resale, and all forms of document delivery. Special rates are available for educational institutions that wish to make photocopies for non-profit educational classroom use.

Permissions may be sought directly from Elsevier Science Global Rights Department, PO Box 800, Oxford OX5 1DX, UK; phone: (+44) 1865 843830, fax: (+44) 1865 853333, e-mail: permissions@elsevier.co.uk. You may also contact Global Rights directly through Elsevier's home page (<http://www.elsevier.com>), by selecting 'Obtaining Permissions'.

In the USA, users may clear permissions and make payments through the Copyright Clearance Center, Inc., 222 Rosewood Drive, Danvers, MA 01923, USA; phone: (+1) (978) 7508400, fax: (+1) (978) 7504744, and in the UK through the Copyright Licensing Agency Rapid Clearance Service (CLARCS), 90 Tottenham Court Road, London W1P 0LP, UK; phone: (+44) 207 631 5555; fax: (+44) 207 631 5500. Other countries may have a local reprographic rights agency for payments.

Derivative Works

Tables of contents may be reproduced for internal circulation, but permission of Elsevier Science is required for external resale or distribution of such material.

Permission of the Publisher is required for all other derivative works, including compilations and translations.

Electronic Storage or Usage

Permission of the Publisher is required to store or use electronically any material contained in this work, including any chapter or part of a chapter.

Except as outlined above, no part of this work may be reproduced, stored in a retrieval system or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without prior written permission of the Publisher.

Address permissions requests to: Elsevier Science Global Rights Department, at the mail, fax and e-mail addresses noted above.

Notice

No responsibility is assumed by the Publisher for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products, instructions or ideas contained in the material herein. Because of rapid advances in the medical sciences, in particular, independent verification of diagnoses and drug dosages should be made.

First edition 2002

Library of Congress Cataloging in Publication Data

A catalog record from the Library of Congress has been applied for.

ISBN: 0-444-50760-4

© The paper used in this publication meets the requirements of ANSI/NISO Z39.48-1992 (Permanence of Paper). Printed in The Netherlands.

PHARMACOCHEMISTRY LIBRARY

ADVISORY BOARD

- T. Fujita** Department of Agricultural Chemistry, Kyoto University, Kyoto, Japan
E. Mutschler Department of Pharmacology, University of Frankfurt, Frankfurt, Germany
N.J. de Souza Research Centre, Wockhardt Centre, Bombay, India
F.J. Zeelen Heesch, The Netherlands

This Page Intentionally Left Blank

CONTENTS

Preface	ix
 <i>A. Hogner, J.S. Kastrup, J. Greenwood, S.B. Vogensen, E.H. Møller, T.B. Stensbøl, J. Egebjerg and P. Krogsgaard-Larsen</i>	
Towards rational design of AMPA receptor ligands: an integrated medicinal, computational, biostructural and molecular pharmacological approach	1
 <i>C.C.A. van Boeckel</i>	
From heparin to synthetic antithrombotics. The pentasaccharide story and follow-up	13
 <i>A. Bruggink</i>	
A new future for synthesis?	21
 <i>M.T. Reetz</i>	
Directed evolution of enantioselective enzymes as catalysts in the production of chiral pharmaceuticals	27
 <i>R. Schoevaart and A.P.G. Kieboom</i>	
At the interface of organic synthesis and biosynthesis	39
 <i>R.E. Hubbard</i>	
What can structure tell us about function in the estrogen receptors?	53
 <i>M. Kouwijzer and J. Mestres</i>	
Molecular docking and dynamics simulations in the ligand binding domain of steroid hormone receptors	57
 <i>S. Kliewer</i>	
Peroxisome proliferator-activated receptors and reverse endocrinology	67
 <i>A.J.R. Heck and C.S. Maier</i>	
Biomolecular mass spectrometry related to drug research	81
 <i>P. Angeli and G. Gaviraghi</i>	
Chemical and biological diversity in drug discovery	95
 <i>J. Gomeza, M. Yamada, A. Duttaroy, W. Zhang, R. Makita, T. Miyakawa, J. Crawley, L. Zhang, H. Shannon, F.P. Bymaster, C.C. Felder, C. Deng and J. Wess</i>	
Muscarine acetylcholine receptor knockout mice: phenotypical analysis and clinical implications	97
 <i>P.F. Zaratini, A. Quattrini, S. Previtali, G. Hervieu and M.A. Scheideler</i>	
Changes in expression of the orphan G-protein coupled receptor GPR7 in human painful peripheral neuropathies	115

V.J. Gillet and P. Willett

Computational methods for the analysis of molecular diversity 125

D. Langley

Enhancing drug discovery by acquisition of chemical diversity 135

P. Seneci

Chemical diversity as a driving force to design and put in practice synthetic strategies leading to combinatorial libraries for lead discovery and lead optimization 147

H. Just, E. Stefan, C. Czupalla, B. Nürnberg, Chr. Nanoff and M. Freissmuth

Beyond G proteins: the role of accessory proteins in G protein-coupled receptor signalling 161

Ph.G. Strange

Mechanisms of action of antipsychotic drugs: the role of inverse agonism at the D₂ dopamine receptor 175

K.E.O. Åkerman, J. Näsman, T. Holmqvist and J.P. Kukkonen

Agonist channeling of α_2 -adrenoceptor function 181

D. Golemi, L. Maveyraud, J. Haddad, W. Lee, A. Ishiwata, K. Miyashita, L.

Mourey, S. Vakulenko, L. Kotra, J. Samama, and S. Mobashery

Antibacterials as wonder drugs and how their effectiveness is being compromised 193

E.P. Greenberg

Pseudomonas aeruginosa quorum sensing: a target for antipathogenic drug discovery 207

I. Chopra, L. Hesse and A. O'Neill

Discovery and development of new anti-bacterial drugs 213

B.B. Zhang

Discovery of small molecule insulin mimetics as potential novel antidiabetic agents 227

L.M. Furness

Expression databases for pharmaceutical lead optimisation 237

R.G. Pertwee

New developments in the pharmacology of cannabinoids 249

Author index 259

Subject index 261

PREFACE

Trends in Drug Research followers or setters

This volume of Pharmacochemistry Library comprises the text of invited lecturers presented at the Noordwijkerhout-Camerino Symposium *Trends in Drug Research*, held in Noordwijkerhout, The Netherlands, from 6-11 May 2001.

During the 13th symposium in the series the question was asked whether medicinal chemists are following trends or perhaps trendsetters. The answer was clear: trendsetters. Through the years of the series - the first one dates back to 1974 - topics of the programme have been developing into almost routine aspects of medicinal chemistry; QSAR, modelling, receptor models.

The 13th symposium fitted perfectly well in this tradition. On the programme were sessions on chemical and biological diversity, on new paradigms in drug action, on new insights in receptor mechanisms. A session which got much attention - and which brought new insights - was on green chemistry, the interface between organic synthesis and biosynthesis.

A special symposium was devoted to the growing problem of resistant micro-organisms and the possibilities to identify new - and better - antibiotics.

In a final session on very recent developments the new finding of small molecules with insulin sensitizing properties received much attention. Would an insulin-mimetic, a small molecule, be possible?

The organizers of the Noordwijkerhout-Camerino Symposia express their sincere thanks to those who supported the 2001 symposium financially: Astra Zeneca, Byk Nederland, DSM, Glaxo Wellcome, Janssen Research Foundation, Lundbeck A/S, E. Merck, Organon Research, Pfizer (Parke Davis), UCB, Yamanouchi Europe.

H. Timmerman,
Chairman Organizing Committee

This Page Intentionally Left Blank

Towards Rational Design of AMPA Receptor Ligands: An Integrated Medicinal, Computational, Biostructural and Molecular Pharmacological Approach

Anders Hogner, Jette S. Kastrup, Jeremy Greenwood, Stine B. Vogensen, Eva H. Møller, Tine B. Stensbøl, Jan Egebjerg¹ and Povl Krogsgaard-Larsen*

Department of Medicinal Chemistry, The Royal Danish School of Pharmacy, 2 Universitetsparken, DK-2100 Copenhagen, Denmark and ¹Department of Molecular Genetics, H. Lundbeck A/S, 9 Ottiliavej, DK-2500 Valby-Copenhagen, Denmark

1. Medicinal Chemistry, a Science Undergoing Rapid Transformations

The field of medicinal chemistry is in a state of swift development and is at present undergoing major restructuring. The molecular biological revolution and the progressing mapping of the human genome have created a new biochemical and biostructural “world order”. These developments have provided new challenges and opportunities for drug research in general and for drug design in particular. The major objectives of the medicinal chemists are transformation of pathobiochemical and - physiological data into a “chemical language” with the aim of designing molecules interacting specifically with the derailed or degenerating processes in the diseased organism.

Potential therapeutic targets are being disclosed with increasing frequency, and this exponential growth will continue during the next decades. In this situation, there is a need for rapid and effective target validation and for accelerated lead discovery procedures. Consequently, most industrial medicinal chemistry laboratories have built up new technologies in order to meet these demands. Key words in this regard are construction of compound libraries, high or ultrahigh throughput screening, accelerated ADME and toxicity tests, and automatized cellular assay systems.

In parallel with this development, biostructure-based drug design and intelligent molecular mimicry or bioisosterism are areas of growing importance in the medicinal chemistry “playing field”. Structural biology is becoming an increasingly important part of molecular biology and biochemistry, and, furthermore, organic chemists are increasingly directing their attention towards synthetic aspects of biomolecules and biologically active compounds biosynthesized by plants and animals. Thus the borderland between biology, biochemistry, and chemistry is rapidly broadening and is becoming the most fruitful working field for innovative and intuitive drug design scientists.

2. Industrial Drug Discovery - Academic Drug Design

Where are the academic medicinal chemistry departments in this area of drug research, which is now undergoing profound changes, and which is moving towards an increasing degree of integration of scientific disciplines? Furthermore, how should medicinal chemistry teaching programmes be organized and taught in this highly dynamic research area? These burning questions need to be effectively addressed, and if the responsible academics fail to meet these challenges, academic medicinal chemistry will degenerate into traditional organic synthesis, from where it originates, or into trivial service functions in relation to industrial drug design and development programmes.

The equipment for automatized combinatorial chemistry and for high throughput screening procedures, now in operation in most industrial medicinal chemistry departments, is expensive, and purchase of such technical facilities is normally far beyond the financial capacity of academic departments. Furthermore, in terms of operation, these automatized procedures are predominantly technical, and although students should understand the prospects and limitations of such technologies, these aspects can only be limited parts of student courses in medicinal chemistry. The scientific challenges of the conversion of solution synthetic chemistry procedures into solid-phase synthetic methodologies are mainly of basic chemical nature, and the development of cell-based assay systems is predominantly a biochemical pharmacological task.

In order to attract the attention of intelligent students, the creative and fascinating nature of drug design must be the underlying theme of basic and advanced student courses in medicinal chemistry. In relation to industrial screening programmes and "hit-finding" procedures, students should be taught that the conversions of "hits" into lead structures and further into drug candidates require advanced synthetic chemistry supported by computational chemistry. Furthermore, these medicinal chemistry approaches should be integrated with molecular pharmacology studies using cloned target receptors, ion channels, or enzymes, expressed in appropriate model systems.

It is beyond doubt that a steadily increasing number of biomolecules will be subjected to X-ray crystallographic structural analysis. The number of enzymes with established three-dimensional structure is now increasing exponentially [1], and this growth will continue during the next decades. Even oligomeric membrane-bound receptors can now be crystallized and subjected to X-ray crystallographic analysis [2], but such analyses of mono- or oligomeric receptors are still hampered by major experimental difficulties. In recent years, however, biostructural scientists have succeeded in crystallizing recombinant versions of the binding domains of a G protein-coupled receptor [3] as well as a ligand-gated ion channel [4]. Structural analyses of these binding domains co-crystallized with agonist and antagonist ligands have already provided insight into the structural basis of receptor-ligand interactions and of receptor activation and blockade.

These breakthroughs in biostructural chemistry have opened up new avenues in drug design. Structural information derived from X-ray analyses of enzyme-inhibitor conglomerates has been and continues to be very valuable for the design of new types of inhibitors. Similar pieces of information derived from studies of receptor binding domains co-crystallized with different types of competitive or noncompetitive ligands undoubtedly will be of key importance in receptor ligand design projects. These approaches which are in the nature of drug design on a rational basis will become important parts of student teaching programmes in medicinal chemistry.

In academic research and teaching, biologically active natural products probably will play a progressively important role as lead structures. Not only do such compounds often possess novel structural characteristics, but they also frequently exhibit unique biological mechanisms of action, although naturally occurring "toxins" typically show nonselective pharmacological effects. By systematic structural modification, including molecular mimicry approaches, it may be possible to "tame" such "toxins" and convert them into leads with specific actions on biofunctions of key importance in diseases. Biologically active natural products undoubtedly will continue to be important starting points for academic drug design projects, and such approaches will continue to be exciting case stories in student medicinal chemistry courses.




Figure 1. Leading academic medicinal chemistry departments or centres capable of establishing innovative collaborative projects with major industrial drug discovery units will optimally have the above "four-leaf clover" integrated composition of expertises.